[144] ServiceTitan, Inc. SEC Filing
Cumberland Pharmaceuticals Inc. (CPIX) filed a Form 4 on 07/11/2025 disclosing insider purchases by director James Jones.
According to the filing, Mr. Jones bought 20 separate lots of 8 common shares each between 06/02/2025 and 06/30/2025 under a Rule 10b5-1 trading plan adopted on 11/14/2024. Purchase prices ranged from $2.60 to $6.00 per share, with the earliest trade executed at $5.20 and the lowest at $2.60, reflecting a notable intra-month share-price decline.
The aggregate acquisition totaled 160 shares, increasing the director鈥檚 direct beneficial ownership from 43,176 shares after the first trade to 43,336 shares after the final trade on 06/30/2025. No derivative securities were involved, and there were no dispositions.
While insider buying generally signals management confidence, the small trade size limits its quantitative impact. Nevertheless, the steady, automated purchases provide incremental insight into insider sentiment during a period of falling share prices.
Cumberland Pharmaceuticals Inc. (CPIX) ha presentato un Modulo 4 il 11/07/2025, rivelando acquisti da parte dell'insider, il direttore James Jones.
Secondo il documento, il Sig. Jones ha acquistato 20 lotti separati di 8 azioni ordinarie ciascuno tra il 02/06/2025 e il 30/06/2025, nell'ambito di un piano di trading Rule 10b5-1 adottato il 14/11/2024. I prezzi di acquisto variavano da 2,60$ a 6,00$ per azione, con la prima operazione eseguita a 5,20$ e il prezzo pi霉 basso a 2,60$, riflettendo un significativo calo del prezzo delle azioni nel corso del mese.
L'acquisizione complessiva ammonta a 160 azioni, aumentando la propriet脿 diretta del direttore da 43.176 azioni dopo la prima operazione a 43.336 azioni dopo l'ultima operazione del 30/06/2025. Non sono stati coinvolti titoli derivati e non ci sono state cessioni.
Pur indicando generalmente fiducia da parte del management, la piccola dimensione delle operazioni limita l'impatto quantitativo. Tuttavia, gli acquisti costanti e automatizzati offrono un'indicazione aggiuntiva sul sentimento interno durante un periodo di calo dei prezzi azionari.
Cumberland Pharmaceuticals Inc. (CPIX) present贸 un Formulario 4 el 11/07/2025, revelando compras internas realizadas por el director James Jones.
Seg煤n el documento, el Sr. Jones compr贸 20 lotes separados de 8 acciones comunes cada uno entre el 02/06/2025 y el 30/06/2025 bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 14/11/2024. Los precios de compra oscilaron entre $2.60 y $6.00 por acci贸n, con la primera operaci贸n ejecutada a $5.20 y la m谩s baja a $2.60, reflejando una notable ca铆da del precio de la acci贸n durante el mes.
La adquisici贸n totaliz贸 160 acciones, aumentando la propiedad directa del director de 43,176 acciones tras la primera operaci贸n a 43,336 acciones despu茅s de la 煤ltima operaci贸n el 30/06/2025. No se involucraron valores derivados ni hubo disposiciones.
Aunque las compras internas generalmente indican confianza en la gesti贸n, el peque帽o tama帽o de las transacciones limita su impacto cuantitativo. No obstante, las compras constantes y automatizadas brindan una visi贸n adicional sobre el sentimiento interno durante un per铆odo de ca铆da en el precio de las acciones.
Cumberland Pharmaceuticals Inc. (CPIX)電� 2025雲� 7鞗� 11鞚检棎 鞚挫偓 James Jones鞚� 雮措秬鞛� 毵れ瀰鞚� 瓿店皽頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟.
鞁犼碃靹滌棎 霐半ゴ氅�, Jones 鞚挫偓電� 2025雲� 6鞗� 2鞚茧秬韯� 6鞗� 30鞚缄箤歆� 2024雲� 11鞗� 14鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 臧侁皝 8欤检敥 20臧滌潣 臧滊硠 毵れ瀰鞚� 歆勴枆頄堨姷雼堧嫟. 毵れ瀰 臧�瓴╈潃 欤茧嫻 $2.60鞐愳劀 $6.00 靷澊鞓�鞙茧┌, 斓滌磮 瓯半灅電� $5.20鞐�, 斓滌爛臧�電� $2.60鞐� 觳搓舶霅橃柎 鞗� 雮� 欤缄皜 頃橂澖鞚� 氚橃榿頃╇媹雼�.
齑� 毵れ瀰 欤检嫕 靾橂姅 160欤�搿�, 觳� 瓯半灅 頉� 43,176欤检榾雿� 鞚挫偓鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 2025雲� 6鞗� 30鞚� 毵堨毵� 瓯半灅 頉� 43,336欤�搿� 歃濌皜頄堨姷雼堧嫟. 韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌ 毵る弰霃� 鞐嗢棃鞀惦媹雼�.
雮措秬鞛� 毵れ瀰鞚� 鞚茧皹鞝侅溂搿� 瓴届榿歆勳潣 鞁犽毳� 雮橅儉雮挫毵�, 瓯半灅 攴滊臧� 鞛戩晞 鞝曤焿鞝� 鞓來枼鞚� 鞝滍暅鞝侅瀰雼堧嫟. 攴鸽熂鞐愲弰 攵堦惮頃橁碃 昃胳頃橁碃 鞛愲彊頇旊悳 毵れ瀰鞚� 欤缄皜 頃橂澖 旮瓣皠 霃欖晥 雮措秬鞛愳潣 鞁Μ毳� 鞝愳鞝侅溂搿� 氤挫棳欷嶋媹雼�.
Cumberland Pharmaceuticals Inc. (CPIX) a d茅pos茅 un formulaire 4 le 11/07/2025, r茅v茅lant des achats d鈥檌niti茅s par le directeur James Jones.
Selon le d茅p么t, M. Jones a achet茅 20 lots distincts de 8 actions ordinaires chacun entre le 02/06/2025 et le 30/06/2025 dans le cadre d鈥檜n plan de trading Rule 10b5-1 adopt茅 le 14/11/2024. Les prix d鈥檃chat variaient de 2,60 $ 脿 6,00 $ par action, la premi猫re transaction ayant 茅t茅 ex茅cut茅e 脿 5,20 $ et la plus basse 脿 2,60 $, refl茅tant une baisse notable du prix de l鈥檃ction au cours du mois.
L鈥檃cquisition totale s鈥櫭﹍猫ve 脿 160 actions, augmentant la propri茅t茅 directe du directeur de 43 176 actions apr猫s la premi猫re transaction 脿 43 336 actions apr猫s la derni猫re transaction le 30/06/2025. Aucun titre d茅riv茅 n鈥檃 茅t茅 impliqu茅 et aucune cession n鈥檃 eu lieu.
Bien que les achats d鈥檌niti茅s signalent g茅n茅ralement la confiance de la direction, la faible taille des transactions limite leur impact quantitatif. N茅anmoins, ces achats r茅guliers et automatis茅s offrent un aper莽u suppl茅mentaire du sentiment des initi茅s durant une p茅riode de baisse des cours.
Cumberland Pharmaceuticals Inc. (CPIX) reichte am 11.07.2025 ein Formular 4 ein, das Insiderk盲ufe des Direktors James Jones offenlegt.
Dem Bericht zufolge kaufte Herr Jones zwischen dem 02.06.2025 und dem 30.06.2025 20 einzelne Tranchen mit jeweils 8 Stammaktien im Rahmen eines am 14.11.2024 eingef眉hrten Rule 10b5-1 Handelsplans. Die Kaufpreise lagen zwischen
Die Gesamterwerbung belief sich auf 160 Aktien, wodurch das direkte wirtschaftliche Eigentum des Direktors von 43.176 Aktien nach dem ersten Handel auf 43.336 Aktien nach dem letzten Handel am 30.06.2025 anstieg. Es waren keine Derivate beteiligt und es gab keine Ver盲u脽erungen.
Obwohl Insiderk盲ufe allgemein als Vertrauenssignal des Managements gelten, begrenzt die geringe Handelsgr枚脽e die quantitative Wirkung. Dennoch geben die stetigen, automatisierten K盲ufe einen zus盲tzlichen Einblick in die Insiderstimmung w盲hrend einer Phase fallender Aktienkurse.
- Consistent insider purchases across 20 trading days indicate continued director participation in the equity.
- Rule 10b5-1 plan disclosure enhances transparency and reduces potential insider-trading concerns.
- Very small aggregate volume (160 shares) limits financial and signalling significance to investors.
- Purchases coincided with a declining share price, suggesting confidence is cautious or merely plan-driven rather than opportunistic.
Insights
TL;DR: Director bought 160 shares in June via 10b5-1 plan; small but positive sentiment, limited financial impact.
Insider activity shows James Jones adding 160 shares at declining prices ($6.00 to $2.60). Although insider buying can be a bullish signal, the transaction value is modest鈥攚ell under $1 million鈥攕o market impact should be limited. The automated nature under Rule 10b5-1 reduces signaling value compared with discretionary open-market purchases. Overall, sentiment positive but immaterial to valuation.
TL;DR: Routine 10b5-1 purchases; governance compliant, impact neutral.
The filing confirms adherence to SEC Rule 10b5-1 with a plan adopted months earlier, mitigating concerns about information asymmetry. No red flags appear in timing or structure: equal lot sizes, daily executions, and transparent footnote disclosure. The small volume relative to existing ownership suggests no material shift in insider exposure. Governance posture remains neutral.
Cumberland Pharmaceuticals Inc. (CPIX) ha presentato un Modulo 4 il 11/07/2025, rivelando acquisti da parte dell'insider, il direttore James Jones.
Secondo il documento, il Sig. Jones ha acquistato 20 lotti separati di 8 azioni ordinarie ciascuno tra il 02/06/2025 e il 30/06/2025, nell'ambito di un piano di trading Rule 10b5-1 adottato il 14/11/2024. I prezzi di acquisto variavano da 2,60$ a 6,00$ per azione, con la prima operazione eseguita a 5,20$ e il prezzo pi霉 basso a 2,60$, riflettendo un significativo calo del prezzo delle azioni nel corso del mese.
L'acquisizione complessiva ammonta a 160 azioni, aumentando la propriet脿 diretta del direttore da 43.176 azioni dopo la prima operazione a 43.336 azioni dopo l'ultima operazione del 30/06/2025. Non sono stati coinvolti titoli derivati e non ci sono state cessioni.
Pur indicando generalmente fiducia da parte del management, la piccola dimensione delle operazioni limita l'impatto quantitativo. Tuttavia, gli acquisti costanti e automatizzati offrono un'indicazione aggiuntiva sul sentimento interno durante un periodo di calo dei prezzi azionari.
Cumberland Pharmaceuticals Inc. (CPIX) present贸 un Formulario 4 el 11/07/2025, revelando compras internas realizadas por el director James Jones.
Seg煤n el documento, el Sr. Jones compr贸 20 lotes separados de 8 acciones comunes cada uno entre el 02/06/2025 y el 30/06/2025 bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 14/11/2024. Los precios de compra oscilaron entre $2.60 y $6.00 por acci贸n, con la primera operaci贸n ejecutada a $5.20 y la m谩s baja a $2.60, reflejando una notable ca铆da del precio de la acci贸n durante el mes.
La adquisici贸n totaliz贸 160 acciones, aumentando la propiedad directa del director de 43,176 acciones tras la primera operaci贸n a 43,336 acciones despu茅s de la 煤ltima operaci贸n el 30/06/2025. No se involucraron valores derivados ni hubo disposiciones.
Aunque las compras internas generalmente indican confianza en la gesti贸n, el peque帽o tama帽o de las transacciones limita su impacto cuantitativo. No obstante, las compras constantes y automatizadas brindan una visi贸n adicional sobre el sentimiento interno durante un per铆odo de ca铆da en el precio de las acciones.
Cumberland Pharmaceuticals Inc. (CPIX)電� 2025雲� 7鞗� 11鞚检棎 鞚挫偓 James Jones鞚� 雮措秬鞛� 毵れ瀰鞚� 瓿店皽頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟.
鞁犼碃靹滌棎 霐半ゴ氅�, Jones 鞚挫偓電� 2025雲� 6鞗� 2鞚茧秬韯� 6鞗� 30鞚缄箤歆� 2024雲� 11鞗� 14鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 臧侁皝 8欤检敥 20臧滌潣 臧滊硠 毵れ瀰鞚� 歆勴枆頄堨姷雼堧嫟. 毵れ瀰 臧�瓴╈潃 欤茧嫻 $2.60鞐愳劀 $6.00 靷澊鞓�鞙茧┌, 斓滌磮 瓯半灅電� $5.20鞐�, 斓滌爛臧�電� $2.60鞐� 觳搓舶霅橃柎 鞗� 雮� 欤缄皜 頃橂澖鞚� 氚橃榿頃╇媹雼�.
齑� 毵れ瀰 欤检嫕 靾橂姅 160欤�搿�, 觳� 瓯半灅 頉� 43,176欤检榾雿� 鞚挫偓鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 2025雲� 6鞗� 30鞚� 毵堨毵� 瓯半灅 頉� 43,336欤�搿� 歃濌皜頄堨姷雼堧嫟. 韺岇儩 歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌ 毵る弰霃� 鞐嗢棃鞀惦媹雼�.
雮措秬鞛� 毵れ瀰鞚� 鞚茧皹鞝侅溂搿� 瓴届榿歆勳潣 鞁犽毳� 雮橅儉雮挫毵�, 瓯半灅 攴滊臧� 鞛戩晞 鞝曤焿鞝� 鞓來枼鞚� 鞝滍暅鞝侅瀰雼堧嫟. 攴鸽熂鞐愲弰 攵堦惮頃橁碃 昃胳頃橁碃 鞛愲彊頇旊悳 毵れ瀰鞚� 欤缄皜 頃橂澖 旮瓣皠 霃欖晥 雮措秬鞛愳潣 鞁Μ毳� 鞝愳鞝侅溂搿� 氤挫棳欷嶋媹雼�.
Cumberland Pharmaceuticals Inc. (CPIX) a d茅pos茅 un formulaire 4 le 11/07/2025, r茅v茅lant des achats d鈥檌niti茅s par le directeur James Jones.
Selon le d茅p么t, M. Jones a achet茅 20 lots distincts de 8 actions ordinaires chacun entre le 02/06/2025 et le 30/06/2025 dans le cadre d鈥檜n plan de trading Rule 10b5-1 adopt茅 le 14/11/2024. Les prix d鈥檃chat variaient de 2,60 $ 脿 6,00 $ par action, la premi猫re transaction ayant 茅t茅 ex茅cut茅e 脿 5,20 $ et la plus basse 脿 2,60 $, refl茅tant une baisse notable du prix de l鈥檃ction au cours du mois.
L鈥檃cquisition totale s鈥櫭﹍猫ve 脿 160 actions, augmentant la propri茅t茅 directe du directeur de 43 176 actions apr猫s la premi猫re transaction 脿 43 336 actions apr猫s la derni猫re transaction le 30/06/2025. Aucun titre d茅riv茅 n鈥檃 茅t茅 impliqu茅 et aucune cession n鈥檃 eu lieu.
Bien que les achats d鈥檌niti茅s signalent g茅n茅ralement la confiance de la direction, la faible taille des transactions limite leur impact quantitatif. N茅anmoins, ces achats r茅guliers et automatis茅s offrent un aper莽u suppl茅mentaire du sentiment des initi茅s durant une p茅riode de baisse des cours.
Cumberland Pharmaceuticals Inc. (CPIX) reichte am 11.07.2025 ein Formular 4 ein, das Insiderk盲ufe des Direktors James Jones offenlegt.
Dem Bericht zufolge kaufte Herr Jones zwischen dem 02.06.2025 und dem 30.06.2025 20 einzelne Tranchen mit jeweils 8 Stammaktien im Rahmen eines am 14.11.2024 eingef眉hrten Rule 10b5-1 Handelsplans. Die Kaufpreise lagen zwischen
Die Gesamterwerbung belief sich auf 160 Aktien, wodurch das direkte wirtschaftliche Eigentum des Direktors von 43.176 Aktien nach dem ersten Handel auf 43.336 Aktien nach dem letzten Handel am 30.06.2025 anstieg. Es waren keine Derivate beteiligt und es gab keine Ver盲u脽erungen.
Obwohl Insiderk盲ufe allgemein als Vertrauenssignal des Managements gelten, begrenzt die geringe Handelsgr枚脽e die quantitative Wirkung. Dennoch geben die stetigen, automatisierten K盲ufe einen zus盲tzlichen Einblick in die Insiderstimmung w盲hrend einer Phase fallender Aktienkurse.
FAQ
How many CPIX shares did Director James Jones buy?
Over what dates were the CPIX insider purchases made?
What price range did the director pay for CPIX shares?
What is James Jones鈥� total CPIX share ownership after the transactions?
Were the purchases made under a Rule 10b5-1 plan?
Did the Form 4 report any sales or derivative transactions?
